International research led by University College London (UCL) as part of the ‘Cities Changing Diabetes’ partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.
More than two thirds of the world’s 400 million people with diabetes live in urban areas.1,2 The year-long study for Cities Changing Diabetes, a unique public-private-academic partnership, sought to better understand what makes people vulnerable to type 2 diabetes in cities in order to inform solutions for one of the most pressing modern-day public health challenges. To explore this complex issue, more than 550 interviews were undertaken with at-risk and diagnosed people in five major cities – Copenhagen, Houston, Mexico City, Shanghai and Tianjin.
“By largely focusing on biomedical risk factors for diabetes, traditional research has not adequately accounted for the impact of social and cultural drivers of disease,” says David Napier, Professor of Medical Anthropology, UCL. “Our pioneering research will enable cities worldwide to help populations adapt to lifestyles that make them less vulnerable to diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7690951-study-rethink-rise-diabetes-in-cities/
Duchesnay USA launched a new online video series today about pregnancy health and morning sickness, which many don’t know is a medical condition called Nausea and Vomiting of Pregnancy (NVP). The series, entitled Navigating Morning Sickness, premiered with three videos about pregnancy nutrition, medication safety and the potential impact of NVP on a pregnant woman’s life. Additional new videos will be released throughout November and December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64373-duchesnay-usa-online-video-series-pregnancy-morning-sickness
The Crohn’s & Colitis Foundation of America (CCFA) is collaborating with the University of North Carolina School of Medicine (UNC) to create a research partnership between patients with inflammatory bowel disease (IBD) and the scientific community. CCFA Partners is a “patient-powered research network” for Crohn’s disease and ulcerative colitis (collectively known as IBD) that uses state-of-the-art bioinformatics to engage and gather information from patients that researchers can study and analyze along with clinical and other patient-generated data.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449851-crohn-s-colitis-foundation-ccfa-ibd/
Vestergaard, a global company dedicated to improving the health of disadvantaged people, launched its LifeStraw® Follow the Liters program in Kenya this month. As part of this program, high-volume LifeStraw® Community water purifiers have been distributed to provide more than 23 million liters of safe water a year to over 125,000 school children throughout Kenya’s western province.
The distribution is made possible through the LifeStraw® Follow the Liters program which harnesses the collective power of individuals to help solve one of the world’s most pressing issues – lack of access to safe drinking water for people in developing countries. When a consumer purchases any LifeStraw® product, a portion of the funds are used to provide one school child in a developing country with safe drinking water for an entire school year.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7351651-vestergaard-lifestraw-follow-the-liters-program-kenya-safe-water/
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. Last year, award-winning artist Tim McGraw, renowned actress S. Epatha Merkerson and Chef Leticia Moreinos Schwartz called on patients and their loved ones to share their stories – from inspirational successes to daily struggles. Thousands of people from across the country responded, and revealed common challenges like eating healthy, exercising, sticking to a treatment plan and coping with the disease.
“Type 2 diabetes has affected my family, friends and fans, so I’ve learned it can be challenging to manage. It was great to hear from so many people, and I’m impressed by everyone’s dedication to their health,” said McGraw. “The stories we received shed an important light on the similar hardships people in the community face as they work toward achieving their blood sugar goals.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7988751-merck-americas-diabetes-challenge-tim-mcgraw-s-epatha-merkerson-chef-leticia-moreinos-schwartz/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
Alcon, the global leader in eye care and a division of Novartis, is launching a new consumer education campaign called Invisible Edge with the help of Olympic gold- and silver-medalist Laurie Hernandez and two-time gold-medalist Tobin Heath. These star athletes will be shining a spotlight on the importance of clear vision, including the role of top-performing Alcon DAILIES® contact lenses in helping give “everyday” athletes an edge while competing at any level. The Invisible Edge campaign is based on a new survey that found clear eyesight tops the list of attributes that help nearly three in four “everyday” athletes perform at their best.
To view the multimedia release go to:
https://www.multivu.com/players/English/8184651-alcon-dailies-us-olympians/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
This year's Red Dress Collection℠ kicked off Mercedes-Benz Fashion Week in New York City last night with notables such as Lindsey Vonn, AnnaSophia Robb, Colbie Caillat, Giada De Laurentiis, Bella Thorne and Daphne Oz showing off some of the hottest designers’ red gowns to bring awareness to the number 1 killer of women – heart disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/64681-aha-and-macy-s-go-red-for-women/
Announced today by VICHY Laboratoires, the VICHY EXPOSOME GRANT will promote and encourage research activity on the skin exposome. One research grant of 15 000 € will be awarded annually to a research project proposal in the field of exposome and skin.
What is exposome?
The human body is subjected to and responds to complex exposures throughout the lifespan, including exposures from the environment, diet, lifestyle. For this highly complex interaction, the term exposome was recently coined by Dr. Christopher Wild at the World Health Organization‘s International Agency for Research on Cancer.
The exposome analysis, therefore, complements the human genome by providing a comprehensive description of individuals’ lifelong environmental exposures. Exposome research aims to look at the holistic view of the human body’s exposures, how the body responds to those exposures, and their combined effects.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7751451-vichy-announces-exposome-grant/
Nautilus Inc. (NYSE: NLS), a leader in innovative home fitness equipment, today announced the availability of the new Bowflex MAX Trainer™. Designed to take the popular elliptical experience to a new level, the MAX Trainer combines the movement of a traditional elliptical with a stair stepper to create a one-of-a-kind cardio workout.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64969-nautilus-inc-new-high-performance-cardio-machine-bowflex-max-trainer
